The annual ASCO is already over half. This is a comprehensive examination of the pharmaceutical industry's annual investment of 50 billion US dollars in oncology drug development, and is also the stage for the future of more than 100 billion cancer drug market leaders. So far, there have been no new products at the ball king level, but there have been some important developments, and of course some disappointing clinical results. The high response rate of LOXO101 in TRK variants in children and adults with multiple tumors is the first major accident. Although this type of variation is very rare, on average less than 1%, according to Forbes reporter Herper, as long as you use it, you can basically ensure that your tumor will be controlled. This is the second real sensation of kinase inhibitors following the first targeted drug, Gree. If listed, this will also be the second oncology drug approved by Keytruda for pan-dMMR variant tumors by genetic variation rather than tissue classification. The PARP inhibitor Olaparib reduced the risk of progression by 42% in BRCA variant breast cancer, although the survival curves were essentially coincident. PARPi may become a pan-tumor drug that is organized and genetically variant. The CAR-T data released today is exciting. Bluebird's three high-dose groups of BMCA CAR-T (BB2121) produced a 100% response in patients with advanced multiple myeloma. These patients had previously failed on average 7 treatments, and the most used 14 treatments, and finally found the organization today. What is even more exciting is that the BMCA/CD38 double CAR-T of the Chinese company's legendary pharmaceutical industry also produced a 100% response rate, although the number of drugs that failed before the patient was enrolled did not exceed BB21.21. If this result can be repeated, it will be the first time for Chinese companies to become strong competitors in the forefront of new drug development in the world. Must be praised! Another important development is that the combination of Lag3 antibody and PD-1 antibody shows a certain response rate in patients with PD-1 progression and has a quantitative relationship with Lag3 expression (high response patient response rate is 20%). This makes IO no longer limited to PD-1, CTLA4. But ESCO's top-notch IDO inhibitor, Epacostat, was somewhat disappointing. First, there were good people who pointed out that there were three cases of patient response in the update data of Incyte's clinical trials, although this did not violate the ASCO regulations but was suspicious. In addition, the response rate of Epac and Opdivo in ovarian cancer and CRC was lower than expected today (14% and 25%, respectively). Today Incyte shares fell 6%.
Medical Cold Patch
Throat Pain Relief Patch,Throat Pain Relief Pad,Throat Pain Relief Plaster,Antitussive Patch Shandong XiJieYiTong International Trade Co.,Ltd. , https://www.sdxjmedical.com
Throat Pain Relief Patch
[Name] Medical Cold Patch
[Package Dimension] 36 round pieces
The pain relief patch is composed of three layers, namely, backing lining, middle gel and protective film. It is free from pharmacological, immunological or metabolic ingredients.
[Scope of Application] For cold physiotherapy, closed soft tissue only.
[Indications]
The patches give fast acting pain relief for acute and chronic tonsillitis.
[How To Use a Patch]
Please follow the Schematic Diagram. One piece, one time.
The curing effect of each piece can last for 6-8 hours.
[Attention]
Do not apply the patch on the problematic skin, such as wounds, eczema, dermatitis,or in the eyes. People allergic to herbs and the pregnant are advised not to use the medication. If swelling or irritation occurs, please stop using and if any of these effects persist or worsen.notify your doctor or pharmacist promptly. Children using the patch must be supervised by adults.
[Storage Conditions] Store below 30c in a dry place away from heat and direct sunlight.